47 results
8-K
EX-99.1
ECOR
ElectroCore Inc
3 Nov 22
Third quarter 2022 revenue grew 33% over third quarter 2021
4:33pm
)
Pregnant women
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
For more information, please visit
8-K
EX-99.1
ECOR
ElectroCore Inc
14 Oct 22
Results of Operations and Financial Condition
4:10pm
surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically
8-K
EX-99.1
ECOR
ElectroCore Inc
20 Sep 22
Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
8:06am
surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically
8-K
EX-99.1
ECOR
ElectroCore Inc
4 Aug 22
Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and 14% sequentially
4:20pm
nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically significant hypertension
8-K
EX-99.1
x95hkm 5o9ncomi
12 Jul 22
Results of Operations and Financial Condition
10:39am
8-K
EX-99.1
4mwl4tj
5 May 22
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially
12:00am
8-K
EX-99.1
ttunp
12 Apr 22
Results of Operations and Financial Condition
9:58am
8-K
EX-99.1
xnz1y061
15 Mar 22
Results of Operations and Financial Condition
5:00pm
8-K
EX-99.1
59ymp0u08zms4ia
18 Jan 22
Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020
8:55am
8-K
EX-99.1
lbfp 5srlp6
4 Nov 21
Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020
4:43pm
8-K
EX-99.1
w92jg8lm
12 Oct 21
Results of Operations and Financial Condition
8:42am
8-K
EX-99.1
n2r5 zekm0d
20 Sep 21
Other Events
8:40am
8-K
EX-99.1
t5gmt6gcz7o0qyyx5
5 Aug 21
Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially
4:11pm
8-K
EX-99.1
h7gd jzynhjc
6 May 21
Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially
4:23pm
8-K
EX-99.1
9r40efk5i
11 Mar 21
Further reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million in the third quarter 2020
4:15pm
8-K
EX-99.1
2cslvpc z65
17 Feb 21
FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age
8:00am
8-K
EX-99.1
xb8xq
22 Jan 21
Other Events
6:00am